FilingReader Intelligence
Zhifei Biologics greenlit for clinical trials of new vaccine
June 23, 2025 at 12:20 PM UTC•By FilingReader AI
Chongqing Zhifei Biological Products (SZSE:300122) announced the approval for clinical trials of its independently developed tetanus vaccine, a project helmed by its subsidiary, Zhifei Green Bamboo. The approval, granted by the National Medical Products Administration, allows the company to proceed with clinical trials for the prevention of tetanus.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime